This study, sponsored by Tianjin First Central Hospital, aims to evaluate the safety and efficacy of two polyclonal antibody regimens in simultaneous pancreas-kidney transplant recipients. The market for immunosuppressive therapies in transplant medicine is significant, with increasing demand for improved outcomes in high-risk patients. The results of this study could position the sponsor favorably against competitors in the immunosuppressive drug market, particularly if non-inferiority is demonstrated. Given the study's observational nature, it may also provide valuable real-world evidence that could enhance market access strategies and inform pricing models. The focus on a specific patient population (end-stage diabetic nephropathy) may also allow for targeted marketing strategies.